Trevi Therapeutics (TRVI) Competitors $8.25 -1.50 (-15.38%) Closing price 04:00 PM EasternExtended Trading$8.18 -0.06 (-0.79%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI vs. CRNX, KYMR, RARE, TLX, NAMS, VKTX, XENE, AMRX, SRRK, and IMVTShould you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), Ultragenyx Pharmaceutical (RARE), Telix Pharmaceuticals (TLX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), AMNEAL PHARMACEUTICALS (AMRX), Scholar Rock (SRRK), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. Trevi Therapeutics vs. Its Competitors Crinetics Pharmaceuticals Kymera Therapeutics Ultragenyx Pharmaceutical Telix Pharmaceuticals NewAmsterdam Pharma Viking Therapeutics Xenon Pharmaceuticals AMNEAL PHARMACEUTICALS Scholar Rock Immunovant Trevi Therapeutics (NASDAQ:TRVI) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment. Which has more volatility and risk, TRVI or CRNX? Trevi Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Is TRVI or CRNX more profitable? Crinetics Pharmaceuticals' return on equity of -32.28% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -41.44% -38.21% Crinetics Pharmaceuticals N/A -32.28%-29.45% Does the media prefer TRVI or CRNX? In the previous week, Trevi Therapeutics had 7 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 14 mentions for Trevi Therapeutics and 7 mentions for Crinetics Pharmaceuticals. Trevi Therapeutics' average media sentiment score of 1.45 beat Crinetics Pharmaceuticals' score of 1.24 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in TRVI or CRNX? 95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher earnings and valuation, TRVI or CRNX? Trevi Therapeutics has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$47.91M-$0.42-19.64Crinetics Pharmaceuticals$1.04M3,078.96-$298.41M-$4.11-8.27 Do analysts recommend TRVI or CRNX? Trevi Therapeutics presently has a consensus price target of $21.75, indicating a potential upside of 163.64%. Crinetics Pharmaceuticals has a consensus price target of $68.86, indicating a potential upside of 102.52%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Trevi Therapeutics is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 SummaryTrevi Therapeutics beats Crinetics Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition Export to ExcelMetricTrevi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.00B$3.12B$5.78B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-19.6421.3074.5925.92Price / SalesN/A258.41453.9085.92Price / CashN/A45.3337.0859.91Price / Book6.359.6112.156.29Net Income-$47.91M-$53.29M$3.28B$270.85M7 Day Performance17.69%0.29%0.98%3.36%1 Month Performance12.55%8.91%7.20%6.41%1 Year Performance150.00%13.14%63.06%28.26% Trevi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics2.8438 of 5 stars$8.25-15.4%$21.75+163.6%+195.5%$1.00BN/A-19.6420News CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.6943 of 5 stars$35.14-1.3%$68.86+96.0%-33.5%$3.35B$1.04M-8.55210Positive NewsKYMRKymera Therapeutics2.6662 of 5 stars$43.26-0.6%$58.76+35.8%+3.2%$3.11B$47.07M-12.47170Positive NewsRAREUltragenyx Pharmaceutical4.4719 of 5 stars$31.51-1.0%$81.50+158.6%-44.6%$3.07B$560.23M-5.701,294Positive NewsAnalyst ForecastTLXTelix Pharmaceuticals3.6552 of 5 stars$9.05-0.1%$22.33+146.8%N/A$3.07B$516.72M0.00N/AAnalyst ForecastNAMSNewAmsterdam Pharma3.4813 of 5 stars$25.09-7.1%$41.55+65.6%+64.6%$3.04B$45.56M-15.494News CoveragePositive NewsInsider TradeHigh Trading VolumeVKTXViking Therapeutics4.2831 of 5 stars$25.48-5.6%$86.92+241.1%-57.7%$3.03BN/A-16.6520Positive NewsXENEXenon Pharmaceuticals2.3736 of 5 stars$38.19-2.6%$53.30+39.6%-3.7%$3.02B$9.43M-10.76210Positive NewsAMRXAMNEAL PHARMACEUTICALS2.8866 of 5 stars$9.73+1.1%$11.60+19.2%+20.7%$3.02B$2.79B973.978,100Positive NewsSRRKScholar Rock4.4805 of 5 stars$31.58+0.5%$45.75+44.9%+266.4%$3.02B$33.19M-10.85140News CoveragePositive NewsIMVTImmunovant2.4436 of 5 stars$16.37-4.5%$33.60+105.3%-42.2%$2.99BN/A-5.74120Positive News Related Companies and Tools Related Companies CRNX Alternatives KYMR Alternatives RARE Alternatives TLX Alternatives NAMS Alternatives VKTX Alternatives XENE Alternatives AMRX Alternatives SRRK Alternatives IMVT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVI) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
